

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>MANZO MICHAEL P.</u> (Last) (First) (Middle) <u>C/O EYEGATE PHARMACEUTICALS,</u> <u>INC.</u> <u>271 WAVERLEY OAKS ROAD, SUITE</u> <u>108</u> (Street) <u>WALTHAM MA 02452</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>02/12/2015</u>	3. Issuer Name and Ticker or Trading Symbol <u>EYEGATE PHARMACEUTICALS INC [EYEG]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Vice President of Engineering</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned			
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)							
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (right to buy)	(1)	10/16/2016	Common Stock	7,286	0.65	D	
Stock Option (right to buy)	(1)	05/16/2017	Common Stock	7,286	0.65	D	
Stock Option (right to buy)	(1)	04/15/2018	Common Stock	3,436	0.65	D	
Stock Option (right to buy)	(1)	01/23/2019	Common Stock	268	0.65	D	
Stock Option (right to buy)	(1)	01/23/2019	Common Stock	1,366	0.65	D	
Stock Option (right to buy)	(1)	01/29/2020	Common Stock	6,885	0.65	D	
Stock Option (right to buy)	(1)	06/25/2020	Common Stock	4,567	0.65	D	
Stock Option (right to buy)	(1)	01/14/2021	Common Stock	1,366	0.65	D	
Stock Option (right to buy)	(1)	01/14/2021	Common Stock	6,400	0.65	D	
Stock Option (right to buy)	(2)	12/23/2022	Common Stock	10,929	0.65	D	

Explanation of Responses:

1. Immediately exercisable.

2. The option became exercisable as to 33% of the shares underlying the option on Dec. 23, 2013 with 2.79% of the shares underlying the option vesting monthly thereafter.

Remarks:

*Signed under power of attorney on behalf of Reporting Person

/s/ Authorized Signatory* 02/12/2015
** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.